Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) EBIT Margin (2024)

Zentalis Pharmaceuticals (ZNTL) has 1 years of EBIT Margin data on record, last reported at 185.55% in Q4 2024.

  • For Q4 2024, EBIT Margin changed N/A year-over-year to 185.55%; the TTM value through Sep 2025 reached 615.16%, down 9922.0%, while the annual FY2024 figure was 283.57%, N/A changed from the prior year.
  • EBIT Margin reached 185.55% in Q4 2024 per ZNTL's latest filing, down from 61.06% in the prior quarter.
  • Across five years, EBIT Margin topped out at 61.06% in Q1 2024 and bottomed at 185.55% in Q4 2024.